TScan CFO Brian Silver to step down effective July 21, 2023

TScan Therapeutics, Inc.

CFO and Treasurer Brian Silver resigns, effective July 21, 2023, to join an advisory firm in New York.
Silver will continue to provide strategic advice to the company post-departure.
Company has initiated a search for a successor chief financial officer.
Silver noted financial runway into 2026 from convertible note, Amgen partnership, and follow-on financing.
Resignation is not due to any disagreement with TScan's operations, policies, or practices.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Brian Silver

Chief Financial Officer and Treasurer

TCRX · TScan Therapeutics, Inc.

Effective: 2023-07-21
Filed: June 29, 2023, 7:59 PM ET

On June 27, 2023, Mr. Brian Silver informed TScan Therapeutics, Inc. (the “Company”) of his intent to step down from his roles as Chief Financial Officer and Treasurer of the Company, effective July 21, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Brian Silver departed as Chief Financial Officer and Treasurer at TScan Therapeutics, Inc..

Action: step down
Role: Chief Financial Officer and Treasurer

Exact text from the filing

On June 27, 2023, Mr. Brian Silver informed TScan Therapeutics, Inc. (the “Company”) of his intent to step down from his roles as Chief Financial Officer and Treasurer of the Company, effective July 21, 2023.

View on SEC.gov

TScan Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-178075

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.